Cardiol Therapeutics (CRDL) Issues Year-end Update on Operations

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. SPY
5. INTC
6. META
7. AAPL
8. JBLU
9. ANT
10. NVDA

Go back to Cardiol Therapeutics (CRDL) Issues Year-end Update on Operations

Cardiol Therapeutics Announces Year-End 2024 Update on Operations

April 1, 2025 7:29 AM EDT

Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx" administered to patients with symptomatic recurrent pericarditis; results support advancing to the Phase III MAVERIC trial

Completed patient enrollment in the Phase II ARCHER trial evaluating CardiolRx" in patients
with acute myocarditis, with topline data expected in Q2 2025

CardiolRx" granted U.S. FDA Orphan Drug Designation for the treatment of pericarditis,
which includes recurrent pericarditis

Cash and cash equivalents of $30.6 million as of December 31, 2024,
to fund operations into Q3... More